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Available online 21 May 2016AbstractObjectives: To determine the effects of multivitamin vitamin D 300 or 600 units on serum 25 hydroxyvitamin D (25(OH)D) level after 4 weeks
of supplementation in postmenopausal women with vitamin D insufficiency.
Study design: Randomized double-blind, placebo-controlled trial.
Methods: Postmenopausal women who had vitamin D insufficiency were recruited into the study. The participants were randomized to 3 groups
of 4-week treatment period with multivitamin (GPO, Governmental Pharmacy Organization) 2 tablets (contained vitamin D2 amount 600 units),
multivitamin 1 tablet (contained vitamin D2 amount 300 units) or placebo. At baseline and after 4 weeks of supplementation, serum 25(OH)D
were determined with electrochemilumines-cence immunoassay (Cobas, Roche Diagnostics) and level change of 25(OH)D level were compared
among the groups.
Results: Out of 144 participants, 49.3% had vitamin D deficiency (<20 ng/ml) and 50.7% had vitamin D insufficiency (<30 ng/ml). However,
after 4 weeks of the GPO oral multivitamin, serum 25(OH)D levels significantly increased from 19.4 ± 6.3 ng/ml at baseline to 22.2 ± 5.2 ng/ml
(p ¼ 0.01) and from 19.5 ± 5.0 ng/ml to 23.3 ± 5.2 ng/ml (p < 0.01) in the groups receiving vitamin D 300 IU and 600 IU/day, respectively.
Approximately, 10% of those who took vitamin D had serum 25(OH)D level above the insufficiency level within 4 weeks. There was no
significant changes of serum 25(OH)D after 4 weeks in the placebo group.
Conclusions: Daily supplementation of the generic multivitamin containing vitamin D2 300 and 600 IU daily for 4 weeks significantly increased
mean serum 25(OH)D from baseline up above the deficiency level.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).insufficiency as a 25(OH)D< 30 ng/ml (75 nmol/L) [1]. Vitamin
D deficiency is associated with low bone mass and osteoporotic
fractures [2]. Nonetheless, vitamin D insufficiency is associated
with rising PTH when the level is below 30 ng/ml [1,3]. Vitamin
D insufficiency is believed to be common in postmenopausal
women [4]. A survey in Thailand, using the cutoff value of
25(OH)D 35 ng/ml, found that 77.81%ofThai premenopausal
women were considered to have vitamin D insufficiency [5].
In 2011, the Endocrine Society Task Force's published
guideline for evaluation, treatment, and prevention of vitaminlsevier B.V. This is an open access article under the CC BY-NC-ND license
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70 þ years require at least 600 and 800 IU/day of inactive
vitamin D, respectively to maximize bone health. However, to
raise the blood level of 25(OH)D above 30 ng/ml may require
at least 1500e2000 IU/day [1].
Although it is still unclear whether we need such high doses
of vitamin D, a meta-analysis revealed that vitamin D supple-
ment at the dose of 700e800 IU/day was associated with
reduction of hip and non-vertebral fractures in older persons [6].
With the dilemma of which to treat between “vitamin D
deficiency” and “vitamin D insufficiency” which may have
great impact on health expenditure, we are interested to study
the changes of 25(OH)D level after ingestion of a daily dose
of either 300 or 600 IU of an inactive vitamin D containing in
a generic oral multivitamin (Governmental Pharmacy Orga-
nization, GPO) for 4 weeks. The GPO multivitamin is cheap
and locally produced within the country. Oral multivitamin
has been recommended and prescribed arbitrarily in clinical
practice as a supplementation to prevent vitamin D deficiency
and insufficiency which were claimed to have high preva-
lence among Thai postmenopausal women. To address this
issue, we conducted a randomized, double-blind, placebo-
controlled trial to assess serum levels of 25(OH)D in 3 groups
of participants who were blinded to receive a daily dose of
placebo or multivitamin containing 300 IU or 600 IU of
vitamin D.
2. Material and methods
This study was a randomized, double-blind, placebo-
controlled trial conducted from August 2012 to January 2013 at
the Menopause Clinic, King Chulalongkorn Memorial Hospi-
tal. The study has been approved by the Institutional Review
Board of the Faculty of Medicine, Chulalongkorn Univesity
and was conducted in accordance with the Declaration of
Helsinki of Good Clinical Practice. The trial is registered at
Thai Clinical Trials Registration (TCTR20131206001). All
women provided their written, informed consent before
recruitment and had the right to withdraw from the study at any
time. Participants could also be withdrawn from the study at the
discretion of the investigators at any time.
Participants who were included into the study were Thai
postmenopausal women, aged between 50 and 80 years,
ambulatory, community-dwellers, body mass index
between 18.50e25.00 kg/m2, having serum 25(OH)D < 30 ng/
ml and were willing to participate in the study. Participants
were excluded if they were women who used vitamin D-
contained medicine within 12 weeks, having a history of
malignancy, liver disease, renal disease, hyperparathyroidism
disorder, malabsorption, bowel surgery or having abnormal
liver or renal function test.
In this study, we define postmenopausal women as those50
years who had permanent cessation of menstruation for at least
one year or women who underwent bilateral oophorectomy.
Vitamin D insufficiency is defined as a serum 25(OH)
D < 30 ng/ml (75 nmol/L) [1]; Vitamin D deficiency: defined as
a serum 25(OH)D < 20 ng/ml (50 nmol/L) [1].Oral multivitamin (GPO®)contained of Vitamin D2 of
300 IU, nicotinamide 7.5 mg, vitamin B2 0.5 mg, vitamin B1
1 mg, vitamin A 2500 IU and vitamin C 15 mg. Independent
pharmacist dispensed either pre-packed oral multivitamin 1
tablet (Vitamin D2 300) in one opaque capsule or oral
multivitamin (GPO®) 2 tablets in one opaque capsule or pla-
cebo used of folic acid (5 mg) (GPO®) 1 tablet in one opaque
capsule according to the block of three randomization list.
The multivitamin one tablet, two tablets and placebo were
in packages that were identical in appearance. They were
packed in one opaque capsule in opaque envelops and
consecutively numbered for each women according to the
randomization schedule. Each woman was assigned an order
number and received the capsules in the corresponding pre-
packed envelop.
The serum 25(OH)D, serum creatinine, aspartate amino-
transferase, alanine aminotransferase, alkaline phosphatase
level were assessed at baseline. Serum 25(OH)D was
measured by electrochemiluminescence immunoassay (Cobas,
Roche Diagnostics Thailand). The inter-assay and intra-assay
coefficients of variation (CV) of 25(OH)D were 3.52% and
1.53%, respectively. All analytical platforms and immunoas-
says were used in the laboratory for routine testing and were
strictly run in accordance with the manufacturers' guidelines
and according to the laboratories' standard operating pro-
cedures (SOP) for good laboratory practice.
During the “screening and baseline visit (first visit)”, all
participants were interviewed and underwent general physical
examination. Baseline characteristics were recorded in the
case record form. Blood was drawn between 8:00 and 9:30
a.m. after the subjects had fasted for at least 8 h. These were
either analyzed immediately or stored at 20 C until
analyzed. Women with baseline serum 25(OH)D
level < 30 ng/ml were enrolled into the study. All participants
were explained to take a drug for one capsule at 8.00 p.m. for
28 days. The administration of drug was recorded by patients'
self-report on daily record form.
On the follow-up visit (week 2), all participants were inter-
viewed by phone after 2 weeks of drug administration to assess
the treatment compliance and adverse effects. On the 3rd visit
(week 4), serum 25(OH)D was measured after 28 days of sup-
plement. Blood were collected within 3 days after the last pill
intake. Blood were collected and sent to the central laboratory of
King Chulalongkorn Memorial Hospital for the preparation of
serum. The serum samples were either analyzed immediately or
stored at 20 C until analyzed for 25(OH)D level.
Participants' baseline characteristic data such as age, body
mass index (BMI), year since menopause, sun-exposure time,
the use of sun screen and baseline serum 25(OH)D level and
all relevant laboratory data such as serum 25(OH)D, Serum
glutamic oxaloacetic transaminase (SGOT), Serum glutamic
pyruvic transaminase (SGPT), alkaline phosphatase (ALP),
creatinine were obtained. Post-supplement serum 25(OH)D
level and change of serum 25(OH)D level were the primary
outcome measurement.
Sample size was estimated based on a pilot study. A level of
statistical significance of 0.05% and power of study of 90%, we
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total sample size of 144 subjects. Descriptive statistics [mean
standard deviation or median (range) and percentage] were used
to express demographic, baseline and measurement outcome
data. Changes of serum 25(OH)D from baseline in each groups
were analyzed for statistical significance by paired t-test.
Comparisons of measurement outcomes between groups after
intervention were analyzed for statistical significance by
ANCOVA if the data was normally distributed or Man-
neWhitney U test if the data was not normally distributed. A p
level of <.05 was considered statistically significant.
3. Results
Out of 202 participants who were screened with the in-
clusion and exclusion criteria, 144 women were eligible to be
included into the intention-to-treat analysis. The participants'
mean age was 59.8 ± 6.8 years, year since menopause was
11.6 ± 8.6 years and body mass index was 22.4 ± 1.8 kg/m2.
The estimated mean daily sun-exposure time was 1.1 ± 0.9 h.
As a group, baseline characteristics showed no statistical dif-
ferences of age, BMI, year since menopause and sun-exposure
time (Table 1).
At baseline, 49.3% (n ¼ 71) of all participants (n ¼ 144) had
vitamin D deficiency (<20 ng/ml), and 50.7% (n ¼ 73) had
vitamin D insufficiency (<30 ng/ml). However, after 4 weeks of
the GPO oral multivitamin, serum 25(OH)D levels significantly
increased from 19.4 ± 6.3 ng/ml at baseline to 22.2 ± 5.2 ng/ml
and from 19.5 ± 5.0 ng/ml to 23.3 ± 5.2 ng/ml only in the
groups receiving vitamin D 300 IU and 600 IU/day, respectively
(Table 2). While there was no significant changes of serum
25(OH)D after 4-week period in the placebo group.
When looked into the percentages of postmenopausal
women who had vitamin D deficiency, there was a tendency
toward lower percentages of vitamin D deficiency in the
groups taking the GPO multivitamin containing vitamin D 300Table 1
Participants' characteristics.
Placebo 300 IU 600 IU
N 48 48 48
Age (y) 59.6 ± 6.4 60.5 ± 7.7 59.5 ± 6.1
Body mass index (kg/m2) 22.2 ± 1.7 22.7 ± 1.6 22.3 ± 2.1
Year since menopause 11.5 ± 7.4 12.6 ± 9.9 10.5 ± 8.4
Sun-exposure time (h) 1.1 ± 0.9 1.1 ± 1.0 1.0 ± 0.9
Sunscreen % (N ) 68.8 (33) use 68.8 (33) use 58.3 (28) use
Data are presented as mean ± SD or percentage.
Table 2
Serum 25(OH)D (ng/ml) before and after 4 weeks of the supplements within
group comparison.
Serum 25(OH)D (ng/ml) Baseline After 4 weeks Mean change p
Placebo 20.5 ± 5.6 21.0 ± 6.0 0.5 0.40
Vitamin D 300 IU 19.4 ± 6.3 22.2 ± 5.2 2.8 0.01
Vitamin D 600 IU 19.5 ± 5.0 23.3 ± 5.2 3.9 <0.01
Paired T-Test: compared pretreatment and post-treatment intra-group.and 600 IU when compared to the placebo (Table 3). The
mean differences between those who received 300 IU or
600 IU of vitamin D and placebo (using ANCOVA) were
statistical significant but not between the two vitamin D
groups (Table 4).
4. Discussion
Long duration of estrogen deficiency after menopause may
result in osteopenia and osteoporosis [14]. Vitamin D defi-
ciency aggravates osteoporosis and causes osteomalacia with
diffuse muscle pain and muscle weakness [2]. Vitamin D
deficiency has traditionally been defined as a 25(OH)D level
below 20 ng/ml [1]. However, higher 25(OH)D levels are
probably necessary for optimal musculoskeletal function and
normal serum parathyroid hormone level. PTH levels begin to
rise when 25(OH)D levels drop below 30 ng/ml [15]. A
25(OH)D level below 30 ng/ml is therefore defined as Vitamin
D insufficiency which leads to reduced calcium absorption,
elevated serum parathyroid hormone, as a result, increases the
rates of bone resorption and proximal muscle weakness that
compromise gait and balance which may lead to fall and
consequent fracture [15].
The present study reveals that 49.3% of the studied par-
ticipants had vitamin D deficiency and 50.7% had vitamin D
insufficiency. The GPO multivitamin supplementation con-
tained vitamin D2 300e600 IU used in this 4-week study was
shown to raise the mean 25(OH)D from baseline up above the
deficiency level (20 ng/ml). Only 10.4% of women received
vitamin D2 of 300 IU and those received vitamin D2 of 600 IU
had 25(OH)D above the insufficiency level within 4 weeks.
Nevertheless, this depends upon the baseline 25(OH)D level
and the severity of vitamin D deficiency and insufficiency.
The increases of 25(OH)D in our study seems to be less
than those from the aforementioned studies [7e12]. This isTable 3










- Baseline (%), (n) 47.9 (23) 47.9 (23) 52.0 (25)
- After 4 weeks (%), (n) 41.6 (20) 25.0 (12) 22.9 (11)
Vitamin D insufficiency
- Baseline (%), (n) 52.0 (25) 52.0 (25) 47.9 (23)
- After 4 weeks (%), (n) 54.1 (26) 64.5 (31) 66.6 (32)
Vitamin D sufficient
- Baseline (%), (n) 0 0 0
- After 4 weeks (%), (n) 4.2 (2) 10.4 (5) 10.4 (5)
Table 4
Change of serum 25(OH)D levels between groups in relation to dosage of
vitamin D supplementation after 4 weeks.
Comparison between vitamin D groups Mean difference Std. Error p
Vitamin D 600 IU e Placebo 3.270 1.046 0.002
Vitamin D 300 IU e Placebo 2.229 1.046 0.035
Vitamin D 600 IU e Vitamin D 300 IU 1.041 1.046 0.321
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vitamin D. The shorter follow-up duration of which vitamin D,
as one of the fat soluble vitamins, is accumulative with time
may explain a lower mean level at 4 weeks. Recently, a meta-
analysis reveals that vitamin D3 is more efficacious at raising
serum 25(OH)D concentrations than is vitamin D2 [16].
In this study we did not evaluate serum calcium level to
monitor hypercalcemia or investigating for renal calculi due to
the type, dose and duration of vitamin D used in this study was
inactive, low doses and short duration. With the very wide
therapeutic range of inactive vitamin D, we did not expect to
see symptoms of hypercalcemia or occurrence of renal calculi
in this short-term study. This may be in accordance with
previous studies which showed no case of hypercalcemia or
renal stones [17] of which one of the studies gave a weekly
50,000 IU of vitamin D2 to participants for 8 weeks.
As seasons in Bangkok are not much different from one to
the other, the daytime and sunlight exposure may be less
distinct in different seasons of the year when compared with
other different latitudes. Moreover, our subjects were recruited
in the same studied period during September to December
2012. Thus, it may have less significant effects from varying
sunlight exposure. However, we could not eliminate other
confounders such as different intakes of vitamin D from va-
rieties of food source, different percentages of sunscreen used
or the way our participants exposed to sunlight.
Although the study was carefully designed as randomized,
double-blind, placebo-controlled trial in order to minimize
bias that might incur from treatment awareness, practically it
might not be able to absolutely eliminate the clinical differ-
ence between the placebo and treatment. Since the oral mul-
tivitamins used in this study contained various types and doses
of vitamin B which might have typical smell that participants
could detect the distinction from placebo. This may compro-
mise the blinding of the study. Whether the small but signif-
icant increase of 25(OH)D levels among the treatment groups
over the placebo has any clinically implication is needed to be
elucidated. With respect to the timing of blood collection after
4 weeks, the period of 1e3 days from the last pill will have
effect over 25(OH)D levels, and is still needed to be clarified.
5. Conclusion
Daily supplementation of the generic multivitamin con-
taining vitamin D2 of 300 and 600 IU daily for 4 weeks
significantly increased mean serum 25(OH)D from baseline up
above the deficiency level. However, only 10.4% of post-
menopausal women taking the oral multivitamin D2 contain-
ing vitamin D2 (300 IU or 600 IU daily) were able to achieve
vitamin D levels considered to be sufficient (>30 ng/ml).
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analysis and manuscript development.What is already known on this topic
Previous policy in the Menopause Clinic, King Chula-
longkorn Memorial Hospital was to provide daily supple-
mentation of the generic multivitamin containing vitamin D2
of 300 or 600 IU to postmenopausal women for prevent
vitamin D insufficiency and osteoporosis.
In 2011, the Endocrine Society Task Force's published
guideline for evaluation, treatment, and prevention of
vitamin D deficiency suggested that all adults age 50e70
and 70 þ years require at least 600 and 800 IU/day of
inactive vitamin D, respectively to maximize bone health.
However, to raise the blood level of 25(OH)D above 30 ng/
ml (vitamin D insufficiency) may require at least
1500e2000 IU/day [1].
What this study adds
Daily supplementation of the generic multivitamin con-
taining vitamin D2 of 300 or 600 IU seem less effective to
prevent vitamin D insufficiency and osteoporosis in post-
menopausal women.
The findings support the increasing of daily supplementa-
tion vitamin D dosage should necessary for prevent vitamin D
insufficiency and osteoporosis recommended by the guideline.
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